Published in Blood on January 01, 2001
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2007) 2.33
Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci U S A (2006) 2.06
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 1.93
Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest (2007) 1.42
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol (2005) 1.26
Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell (2009) 1.26
Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol (2008) 1.19
Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol (2014) 1.15
High-definition mapping of retroviral integration sites defines the fate of allogeneic T cells after donor lymphocyte infusion. PLoS One (2010) 1.07
A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc Natl Acad Sci U S A (2008) 1.06
An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther (2010) 1.00
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant (2014) 0.99
Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther (2010) 0.98
Improving the safety of cell therapy with the TK-suicide gene. Front Pharmacol (2015) 0.96
Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol (2014) 0.94
Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. Hum Gene Ther (2011) 0.93
Adoptive T-cell therapy: adverse events and safety switches. Clin Transl Immunology (2014) 0.91
Antiviral T-cell therapy. Immunol Rev (2014) 0.91
Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene. PLoS One (2013) 0.89
Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) (2015) 0.89
Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Adv Hematol (2012) 0.87
Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int (2011) 0.86
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther (2012) 0.83
Accelerating immune reconstitution after hematopoietic stem cell transplantation. Clin Transl Immunology (2014) 0.81
Progress and prospects for engineered T cell therapies. Br J Haematol (2014) 0.80
In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. Mol Ther (2013) 0.79
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol (2017) 0.77
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol (2012) 0.77
iCaspase 9 Suicide Gene System. Methods Mol Biol (2015) 0.77
Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study. Leukemia (2014) 0.76
Haploidentical HSCT: a 15-year experience at San Raffaele. Bone Marrow Transplant (2015) 0.76
Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells. Immunology (2008) 0.76
Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts. Gene Ther (2016) 0.75
Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy. World J Stem Cells (2015) 0.75
Haploidentical hematopoietic stem-cell transplantation in adults. Bone Marrow Res (2011) 0.75
Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol (2016) 0.75
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med (2017) 0.75
Caspase-9: structure, mechanisms and clinical application. Oncotarget (2017) 0.75
Editorial: Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol (2015) 0.75
Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. Gene Ther (2016) 0.75
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c. Cell (1982) 3.38
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med (1984) 3.06
Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem (1998) 2.80
Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem (1996) 2.78
Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol (1996) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
Viridans streptococcal bacteraemia in patients with neutropenia. Lancet (1995) 2.46
Soft-tissue sarcoma and non-Hodgkin's lymphoma clusters around a municipal solid waste incinerator with high dioxin emission levels. Am J Epidemiol (2000) 2.41
Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet (1996) 2.41
Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J (2004) 2.40
Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS) Am J Clin Pathol (1998) 2.35
Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest (1995) 2.29
Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function. J Exp Med (1985) 2.27
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med (1985) 2.18
Purification and properties of cytoplasmic granules from cytotoxic rat LGL tumors. J Immunol (1984) 2.16
Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun (1997) 2.14
Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med (1985) 2.14
Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells. J Immunol (1981) 2.12
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 2.06
Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: incidence and consequences. Am J Transplant (2013) 2.03
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia (2003) 1.96
Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother (1992) 1.92
Are complicated forms of celiac disease cryptic T-cell lymphomas? Blood (1998) 1.87
Therapy-related acute promyelocytic leukemia. J Clin Oncol (2003) 1.82
Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia (2001) 1.82
Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem (1995) 1.80
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol (2000) 1.77
Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones. J Immunol (1984) 1.75
Chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 1.74
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol (2000) 1.73
Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A (1999) 1.72
Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol (1986) 1.72
Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood (1993) 1.71
Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol (1998) 1.70
Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol (1996) 1.70
Peripheral clonal elimination of functional T cells. Science (1990) 1.69
p53 mutation is associated with progression in follicular lymphomas. Blood (1993) 1.69
Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ (1994) 1.68
Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood (1992) 1.66
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia molecules. J Exp Med (1981) 1.65
Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol (2001) 1.65
Clonal analysis of the major histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome C. J Immunol (1983) 1.63
The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J Immunol (1983) 1.61
Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.61
Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature (1984) 1.58
The control of chemotherapy-induced emesis. Ann Intern Med (1981) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol (1985) 1.55
Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ (2006) 1.55
Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst (1993) 1.54
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53
T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest (1996) 1.53
Haemodynamic evaluation of pulmonary hypertension. Eur Respir J (2002) 1.53
Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel. Mol Cell Biol (1992) 1.52
Small noncleaved cell lymphoma associated with florid epithelioid granulomatous response. A clinicopathologic study of seven patients. Am J Surg Pathol (1993) 1.51
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J (2007) 1.51
Natural killer activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry. J Immunol (1981) 1.51
Gene complementation. Neither Ir-GLphi gene need be present in the proliferative T cell to generate an immune response to Poly(Glu55Lys36Phe9)n. J Exp Med (1980) 1.49
Liposomes as targets for granule cytolysin from cytotoxic large granular lymphocyte tumors. Proc Natl Acad Sci U S A (1984) 1.49
Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant (2000) 1.48
Growth hormone as an immunomodulating therapeutic agent. Immunol Today (2000) 1.48
Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation (1997) 1.46
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol (1993) 1.46
Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood (1994) 1.46
Clinical and practical value of human cytomegalovirus DNAemia detection by semi-nested PCR for follow-up of BMT recipients. Bone Marrow Transplant (1995) 1.45
Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases. Am J Surg Pathol (1993) 1.45
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant (2000) 1.44
Lymphocytic lymphoma of intermediate differentiation--mantle zone lymphoma: a distinct subtype of B-cell lymphoma. Hum Pathol (1987) 1.44
Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood (1994) 1.43
Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol (1999) 1.42
Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med (1984) 1.41
Amelioration of reperfusion injury by pentoxifylline after lung transplantation. The Université Paris-Sud Lung Transplant Group. J Heart Lung Transplant (1995) 1.40
Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer (1990) 1.40
Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1. J Immunol (1989) 1.39
Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol (2000) 1.39